Glenmark Pharma is expected to report its Q3 earnings on Friday. The company is expected to report single-digit revenue growth at around 4.7 percent. Margins could be under pressure and 15.5 percent is what the street is expecting with a profit of around Rs 177 crore.
Single-digit revenue growth is expected on account of sluggish US sales. In the last quarter, there was an increase of around $16 million on quarter-on-quarter (QoQ) basis in US sales. But in this quarter, the expectation is that there could be a decline of around $10 million on QoQ basis owing to price competition.
In terms of the India portfolio, the business is expected to be steady and see a growth of 12 percent.